NEKVINDOVA, J., A. MRKVICOVA, V. ZUBANOVA, A.H. VACULOVA, P. ANZENBACHER, P. SOUCEK, Lenka RADOVÁ, Ondřej SLABÝ, Igor KISS, J. VONDRACEK, A. SPICAKOVA, Lucia BOHOVICOVÁ, P. FABIAN, Z. KALA and V. PALICKA. Hepatocellular carcinoma: Gene expression profiling and regulation of xenobiotic-metabolizing cytochromes P450. Biochemical Pharmacology. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, vol. 177, JUL, p. 113912-113922. ISSN 0006-2952. doi:10.1016/j.bcp.2020.113912. 2020.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Hepatocellular carcinoma: Gene expression profiling and regulation of xenobiotic-metabolizing cytochromes P450
Authors NEKVINDOVA, J., A. MRKVICOVA, V. ZUBANOVA, A.H. VACULOVA, P. ANZENBACHER, P. SOUCEK, Lenka RADOVÁ (203 Czech Republic, belonging to the institution), Ondřej SLABÝ (203 Czech Republic, belonging to the institution), Igor KISS (203 Czech Republic, belonging to the institution), J. VONDRACEK, A. SPICAKOVA, Lucia BOHOVICOVÁ (203 Czech Republic, belonging to the institution), P. FABIAN, Z. KALA and V. PALICKA.
Edition Biochemical Pharmacology, OXFORD, PERGAMON-ELSEVIER SCIENCE LTD, 2020, 0006-2952.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.858
RIV identification code RIV/00216224:14740/20:00118001
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1016/j.bcp.2020.113912
UT WoS 000541248000005
Keywords in English Hepatocellular carcinoma; Cytochrome P450; CYP; Drug metabolism; Gene expression; Non-coding RNA
Tags 14110513, 14110811, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 25/1/2021 10:34.
Abstract
Hepatocellular carcinoma (HCC) remains a highly prevalent and deadly disease, being among the top causes of cancer-related deaths worldwide. Despite the fact that the liver is the major site of biotransformation, studies on drug metabolizing enzymes in HCC are scarce. It is known that malignant transformation of hepatocytes leads to a significant alteration of their metabolic functions and overall deregulation of gene expression. Advanced stages of the disease are thus frequently associated with liver failure, and severe alteration of drug metabolism. However, the impact of dysregulation of metabolic enzymes on therapeutic efficacy and toxicity in HCC patients is largely unknown. Here we demonstrate a significant down-regulation in European Caucasian patients of cytochromes P450 (CYPs), the major xenobiotic-metabolizing enzymes, in HCC tumour samples as compared to their surrounding non-cancerous (reference) tissue. Moreover, we report for the first time the association of the unique CYP profiles with specific transcriptome changes, and interesting correlations with expression levels of nuclear receptors and with the histological grade of the tumours. Integrated analysis has suggested certain co-expression profiles of CYPs with lncRNAs that need to be further characterized. Patients with large tumours with down-regulated CYPs could be more vulnerable to drug toxicity; on the other hand, such tumours would eliminate drugs more slowly and should be more sensitive to pharmacotherapy (except in the case of pro-drugs where activation is necessary).
PrintDisplayed: 20/4/2024 00:35